• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Grove, Inc. Announces Fiscal Year 2021 Audited Financial Results

    9/29/21 8:00:00 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRVI alert in real time by email

    Revenues Reach $24.1 Million, a 250% Increase Over 2020

    Net Earnings of $2.9 Million or $.25 Per Share

    HENDERSON, NV, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced audited financial results for its fiscal year ended June 30, 2021 which surpassed preliminary results issued on June 28, 2021.   Investors are encouraged to read the Company's annual report on Form 10-K which was filed with the Securities and Exchange Commission (the "SEC"), contains additional information, and is posted at https://groveinc.io/

    Financial Highlights

    • $24.1 million in revenue
    • $2.9 million in net income
    • $0.25 basic earnings per share
    • $2.9 million in cash flow provided by operations
    • $3.2 million in adjusted EBITDA
    • Strong margin expansion quarter over quarter
    • Strong revenue growth quarter over quarter
    • 4th Quarter revenues of $10.64 million surpassed a 361% growth over 4th quarter revenues in the prior year

    Allan Marshall, Chief Executive Officer of Grove, stated, "Our team surpassed every internal and external projection for revenue growth, income growth, earnings per share and customer acquisition numbers. We finished the year with exceptional growth and significant momentum in the second half of the year. Our team has found a way to grow while maintaining profits in an industry that historically has not been able to produce these types of results. We enter 2022 with momentum and look to continue our outperformance in the current year."

    Andrew Norstrud, Chief Financial Officer of Grove, stated, "Cash flow quarter over quarter exceeded our projections and ended with our strongest quarter to date. The company finished the quarter with $14.5 million in cash and minimal debt that has since been paid. The balance sheet is strong with net working capital of $12.5 million and stockholders' equity of $21.2 million. The company's financial position strengthened every quarter and we finished with great momentum."

    Liquidity and Capital Resources

    Working Capital

      As of

    June 30, 2021
      As of

    June 30, 2020
     
    Current assets $18,293,083  $2,649,674 
    Current liabilities $5,819,161  $3,519,434 
    Working capital $12,473,922  $(869,760)



    Cash Flows

      Years Ended June 30, 
      2021  2020 
    Cash flows provided by (used in) operating activities $2,939,306  $(4,164,746)
    Cash flows used in investing activities  (1,281,007)  (1,462,915)
    Cash flows provided by financing activities  11,988,395   2,817,746 
    Net increase (decrease) in cash during period $13,646,694  $(2,809,915)



    At June 30, 2021, the Company had cash of $14,534,211 or an increase of $13,646,694 from June 30, 2020. The increase of cash provided by operating activities is primarily related to the net income and the sale of the Company common stock.

    About Grove, Inc.

    Grove, Inc. is in the business of developing, producing, marketing and selling quality products and end consumer products containing the industrial hemp plant extract Cannabidiol ("CBD"), as well as diversified products in other verticals. The Company sells to numerous consumer markets including the botanical, beauty care, pet care and functional food sectors. It seeks to take advantage of an emerging worldwide trend to re-energize the production of industrial hemp and to foster its many uses for consumers.

    Company Contact

    Andrew Norstrud

    Email: [email protected]

    Phone: (702) 332-5591

    Investor Relations Contact

    TraDigital IR

    John McNamara

    Email: [email protected]

    Phone: (917) 658-2602

    Forward-Looking Statements

    This press release contains statements that constitute "forward-looking statements," including with respect to the Company's business strategy, product development and industry trends. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Use of Non-GAAP Financial Measures

    The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to establish operational goals, for compensation plans, to measure debt service capability, for capital expenditure planning and to determine working capital needs and believes that these are useful financial measures also used by investors. Non-GAAP adjusted EBITDA is defined as GAAP net income or net loss before interest, taxes, depreciation and amortization (EBITDA) adjusted for the non-cash stock compensation and stock option expense, acquisition, integration & restructuring expenses, charges and gains or losses from extinguishment of debt and other non-cash items. Non-GAAP EBITDA and non-GAAP adjusted EBITDA are not terms defined by GAAP and, as a result, the Company's measure of non-GAAP EBITDA and non-GAAP adjusted EBITDA might not be comparable to similarly titled measures used by other companies. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP financial measures discussed above, however, should be considered in addition to, and not as a substitute for, or superior to net income or net loss as reported for GAAP on the Consolidated Statements of Operations, cash and cash flows on the Consolidated Statement of Cash Flows or other measures of financial performance prepared in accordance with GAAP, and as reflected on the Company's financial statements prepared in accordance with GAAP. These non-GAAP financial measures are not a substitute for or presented in lieu of financial measures provided by GAAP and all measures and disclosures of financial information pursuant to GAAP should be read to obtain a comprehensive and thorough understanding of the Company's financial results. The reconciliations of non-GAAP EBITDA and non-GAAP adjusted EBITDA to GAAP operating income (loss) and/or GAAP net income (net loss) referred to in the highlights or elsewhere are provided in the schedules that are a part of this document.

    Reconciliation of Non-GAAP Adjusted EBITDA to GAAP Net Income (Net Loss)
    Year Ended June 30,
           
      2021  2020 
    Net income (Net loss) GAAP $2,978,948  $(5,383,673 )
    Income tax  (1,282,815)   - 
    Interest expense, net  530,449   138,406 
    Depreciation and amortization  1,030,021   611,346 
    Stock compensation  738,932   372,770 
    Impairment of lease cancellation  -   588,347 
    Gain on lease settlement  (387,860 )  - 
    Gain on SBA PPP loan extinguishment   (403,277 )  - 
    Gain on sale of asset  (8,708 )  (180,211 )
    Non-GAAP adjusted EBITDA $     3,195,690  $(3,853,015 )

      



    Grove Inc

    Consolidated Balance Sheets

      June 30,  June 30, 
      2021  2020 
           
    ASSETS      
    Current assets      
    Cash $14,534,211  $887,517 
    Accounts receivable, net of allowance for doubtful accounts of $57,500 and $10,000, respectively  1,277,662   165,147 
    Inventory  2,094,952   1,448,448 
    Prepaid expenses and other current assets  386,258   148,562 
    Total current assets  18,293,083   2,649,674 
             
    Property and equipment, net  2,832,400   1,687,273 
    Intangible assets, net  1,845,166   1,240,260 
    Goodwill  2,413,813   493,095 
    Deferred tax asset  1,403,591   - 
    Other assets  49,068   37,068 
    Right-of-use asset  417,443   294,835 
    Total other assets  8,961,481   3,752,531 
             
    Total assets $27,254,564  $6,402,205 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current liabilities        
    Accounts payable $1,604,723  $484,333 
    Accrued compensation  1,020,936   195,399 
    Deferred revenue  485,973   473,320 
    Accrued liabilities  296,021   221,664 
    Acquisition payable  1,764,876   - 
    Current portion of notes payable  447,100   183,595 
    Convertible notes payable  -   1,500,000 
    Current portion of operating lease payable  199,532   461,123 
    Total current liabilities  5,819,161   3,519,434 
             
    Notes payable, net of current portion  -   365,350 
    Operating lease payable, net of current portion  217,430   338,040 
    Total long-term liabilities  217,430   703,390 
             
    Commitments and contingencies  -   - 
             
    Stockholders' equity        
    Preferred stock, $0.001 par value, 100,000,000 shares authorized, and 500,000 and 0 shares issued and outstanding, respectively  500   - 
    Common stock, $0.001 par value, 100,000,000 shares authorized, and 15,262,394 and 10,222,223 shares issued and outstanding, respectively  15,262   10,223 
    Additional paid in capital  25,372,247   7,314,341 
    Accumulated deficit  (4,170,036)  (7,098,984)
    Total stockholders' equity attributable to Grove, Inc.  21,217,973   225,580 
    Non-controlling interest in subsidiary  -   1,953,801 
    Total stockholders' equity  21,217,973   2,179,381 
             
    Total liabilities and stockholders' equity $27,254,564  $6,402,205 



    Grove Inc.

    Consolidated Statements of Operations

      Year Ended June 30, 
      2021  2020 
           
    Revenue      
    Product revenue  24,095,025   6,159,013 
    Trade show revenue  -   1,253,847 
       24,095,025   7,412,860 
             
    Product costs  12,196,123   4,280,909 
    Trade show costs  -   561,988 
       12,196,123   4,842,897 
             
    Gross profit  11,898,902   2,569,963 
             
    Operating expenses        
    Sales and marketing  2,388,211   1,370,964 
    General and administrative expenses  8,083,954   6,037,329 
       10,472,165   7,408,293 
             
    Income (loss) from operations  1,426,737   (4,838,330 )
             
    Other expense (income), net        
    Interest expense (income), net  530,449   138,406 
    Gain on sale of assets  (8,708 )  (180,211 )
    Gain on SBA PPP loan extinguishment  (403,277 )  - 
    Settlement of cancelled lease  (387,860 )  - 
    Impairment of cancelled lease expense  -   588,347 
             
    Other expense (income), net  (269,396 )  546,542 
             
    Income (loss) before income tax  1,696,133   (5,384,872 )
             
    Income tax benefit (expense) 1,282,815   - 
             
    Net income (loss)  2,978,948   (5,384,872 )
    Net loss attributable to noncontrolling interest  -   (1,199 )
    Deemed dividend related to the issuance of Series A Preferred Stock  (50,000 )  - 
    Net income (loss) attributable to Grove, Inc. $2,928,948  $(5,383,673 )
             
    Basic income (loss) per share $0.25  $(0.53 )
             
    Diluted income (loss) per share $0.21  $(0.53 )
             
    Weighted average shares outstanding  11,930,378   10,097,075 
             
    Fully diluted weighted average shares outstanding  14,257,934   10,097,075 

      



    Get the next $GRVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRVI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Grove, Inc. Announces Name and Symbol Change to Upexi, Inc. "UPXI"

    HENDERSON, Nev., Aug. 17, 2022 /PRNewswire/ -- Grove Inc. (NASDAQ:GRVI), a market leader in Amazon and eCommerce brand ownership and aggregation, announces that today, August 17, 2022, its trading name on the Nasdaq officially changed from "Grove Inc." to "Upexi, Inc." and its ticker symbol changed from "GRVI" to "UPXI". This accompanies previous press releases notifying investors of this change. CEO Allan Marshall stated, "Last month, we announced our growth strategy in a letter to shareholders that focused on our acquisition plan to bring more, profitable eCommerce brands in various industries under our umbrella. Moving to a new name and stock ticker is a reflection of the progress we have

    8/17/22 4:05:00 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sidoti's August Micro-Cap Virtual Conference

    Presentation Times and Weblinks Released for Over 50 Presenting CompaniesWednesday and Thursday, August 17-18, 2022NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.Presentation AgendaWednesday, August 17th, 2022 (Day 1)*All Times EDT8:30-9:00Mativ Holdings, Inc. (MATV)Brenmiller Energy, Ltd. (BNRG)Sify Technologies Ltd (SIFY)9:15-9:45MISTRAS Group (MG)Bassett Furniture (BSET)Silvercrest Asset Management Group (SAMG)10:00-10:30Anebulo Pharmaceuticals (ANEB)*****

    8/16/22 3:00:00 PM ET
    $AIRI
    $ANEB
    $APRN
    Military/Government/Technical
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Update: Grove, Inc. to Present at Sidoti August Microcap Conference

    HENDERSON, NV , Aug. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove Inc. (GRVI) announced today that Allan Marshall, Chief Executive Officer, is scheduled to present virtually at the Sidoti & Company, August Virtual Microcap Conference on Wednesday, August 17, 2022 at 3:15 pm ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_FqCzxA3xTbOsMXr-Ml5X7Q Grove will also host virtual one-on-ones with investors throughout the conference.  To register for the presentation of a one-on-one meeting, visit https://www.sidoti.com/events/august-micro-cap-virtual-conference. Registration is free and you are not required to be a Sidoti & Company client. 

    8/10/22 10:56:39 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    SEC Filings

    View All

    Grove Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/15/22 4:05:24 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Grove Inc.

    EFFECT - UPEXI, INC. (0001775194) (Filer)

    12/5/22 12:15:12 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grove Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    12/2/22 9:15:45 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Marshall Allan bought $63,909 worth of shares (17,303 units at $3.69), increasing direct ownership by 0.68% to 2,575,081 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    1/11/23 4:56:21 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $49,320 worth of shares (12,000 units at $4.11), increasing direct ownership by 0.47% to 2,557,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/13/22 5:48:52 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Marshall Allan bought $73,161 worth of shares (18,475 units at $3.96), increasing direct ownership by 0.73% to 2,545,778 units

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/5/22 3:24:06 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Financials

    Live finance-specific insights

    View All

    Grove, Inc. Announces Fiscal Year 2021 Audited Financial Results

    Revenues Reach $24.1 Million, a 250% Increase Over 2020 Net Earnings of $2.9 Million or $.25 Per Share HENDERSON, NV, Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced audited financial results for its fiscal year ended June 30, 2021 which surpassed preliminary results issued on June 28, 2021.   Investors are encouraged to read the Company's annual report on Form 10-K which was filed with the Securities and Exchange Commission (the "SEC"), contains additional information, and is posted at https://groveinc.io/ Financial Highlights $2

    9/29/21 8:00:00 AM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:08:22 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:48 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Grove Inc.

    SC 13G - GROVE, INC. (0001775194) (Subject)

    2/14/22 4:07:14 PM ET
    $GRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care